News

GBT440 is an oral, once-daily SCD therapy that works by increasing hemoglobin’s affinity for oxygen. The company is investigating the drug candidate in both healthy subjects and SCD

This study aims to include CD19-positive Acute Lymphoblastic Leukemia (ALL) patients. Other eligibility criteria to enter clinical trials will be assessed by the investigators. "It has been a

The acquisition provides Agenus the ability to accelerate the development of new cancer vaccines and other single agent immuno-oncology approaches, as well as combination therapies. "PhosImmune’s groundbreaking neoantigen

Patients suffering from these severe gout indications accumulate uric acid deposits in joints and tissues, which can cause debilitating pain and damage to joints and organs. SEL-212, the

The randomized, double-blind, placebo-controlled, registration-quality Phase 2 clinical trial AtEase is being conducted at about 25 US sites. The study has been designed to assess the safety of

L-DOS47 is the company’s first immunoconjugate based drug candidate in development based on its DOS47 platform technology designed to use a new approach to amend the microenvironmental conditions

The phase 1/2 open-label, multi-center, clinical trial is for patients with CD30-expressing relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas (NHL), including diffuse large B-cell lymphoma (DLBCL), peripheral

The ongoing phase-2 clinical trial investigates the safety and efficacy of ACP-01, which uses angiogenic progenitor cells to combat the life-threatening complications of CLI. These proprietary cells are

The agreement was executed based on a series of studies using validated animal models of CIPN exposed to unique cannabinoid-based therapies conducted in the lab of Dr. Kenneth